The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.
 
Daniel M. Geynisman
Employment - 2nd.MD
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)
 
Philip Abbosh
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - Adaptive Biotechnologies; natera
Patents, Royalties, Other Intellectual Property - urine biomarkers patent application
 
Eric A. Ross
Patents, Royalties, Other Intellectual Property - Method for Screening Muscle Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy Responsiveness (Inst)
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Pooja Ghatalia
No Relationships to Disclose
 
Fern Anari
No Relationships to Disclose
 
Katherine Ansel
No Relationships to Disclose
 
James Ryan Mark
No Relationships to Disclose
 
Lambros Stamatakis
No Relationships to Disclose
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Rosalia Viterbo
No Relationships to Disclose
 
Eric M. Horwitz
No Relationships to Disclose
 
Mark A Hallman
Consulting or Advisory Role - New Century Health
 
R. Katherine Alpaugh
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - An inflammatory breast cancer cell line was established and is being provided by Fox Chase Cancer Center for research purposes. Royalities are recieved yearly dependent on the number of requests.
 
Richard E. Greenberg
No Relationships to Disclose
 
Marc C. Smaldone
No Relationships to Disclose
 
Robert Guy Uzzo
Consulting or Advisory Role - Amgen; Genentech/Roche; Pfizer; Urogen pharma
Speakers' Bureau - Janssen Oncology
Research Funding - Novartis
 
David Chen
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
 
Alexander Kutikov
Leadership - Visible Health
Stock and Other Ownership Interests - Visible Health
Consulting or Advisory Role - Merck; OncoSec; Pfizer; UroToday
Travel, Accommodations, Expenses - Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Incyte; Infinity Pharmaceuticals; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)